Recombinant ecto-5'-nucleotidase (CD73) has long lasting antinociceptive effects that are dependent on adenosine A1 receptor activation
© Sowa et al; licensee BioMed Central Ltd. 2010
Received: 14 February 2010
Accepted: 14 April 2010
Published: 14 April 2010
Ecto-5'-nucleotidase (NT5E, also known as CD73) hydrolyzes extracellular adenosine 5'-monophosphate (AMP) to adenosine in nociceptive circuits. Since adenosine has antinociceptive effects in rodents and humans, we hypothesized that NT5E, an enzyme that generates adenosine, might also have antinociceptive effects in vivo.
To test this hypothesis, we purified a soluble version of mouse NT5E (mNT5E) using the baculovirus expression system. Recombinant mNT5E hydrolyzed AMP in biochemical assays and was inhibited by α,β-methylene-adenosine 5'-diphosphate (α,β-me-ADP; IC50 = 0.43 μM), a selective inhibitor of NT5E. mNT5E exhibited a dose-dependent thermal antinociceptive effect that lasted for two days when injected intrathecally in wild-type mice. In addition, mNT5E had thermal antihyperalgesic and mechanical antiallodynic effects that lasted for two days in the complete Freund's adjuvant (CFA) model of inflammatory pain and the spared nerve injury (SNI) model of neuropathic pain. In contrast, mNT5E had no antinociceptive effects when injected intrathecally into adenosine A1 receptor (A 1 R, Adora1) knockout mice.
Our data indicate that the long lasting antinociceptive effects of mNT5E are due to hydrolysis of AMP followed by activation of A1R. Moreover, our data suggest recombinant NT5E could be used to treat chronic pain and to study many other physiological processes that are regulated by NT5E.
Ecto-5'-nucleotidase (NT5E) is a glycosyl phosphatidylinositol (GPI)-anchored membrane protein that catalyzes the hydrolysis of extracellular AMP to adenosine . NT5E regulates diverse physiological processes that are modulated by adenosine, including hypoxia, inflammation and epithelial ion transport [2–8]. Recently, we found that NT5E is expressed in peptidergic and nonpeptidergic nociceptive (pain-sensing) neurons and their axon terminals in spinal cord and skin . Based on experiments with Nt5e-/- mice, we established that NT5E accounts for ~50% of all AMP hydrolytic activity in nociceptive neurons .
In addition, we observed that NT5E was extensively co-localized with Prostatic acid phosphatase (PAP, also known as ACPP, Fluoride-resistant acid phosphatase or thiamine monophosphatase) in nociceptive neurons. Like NT5E, PAP functions as an ectonucleotidase in nociceptive neurons by hydrolyzing AMP to adenosine [10, 11]. Both Pap-/- and Nt5e-/- mice show enhanced thermal hyperalgesia in animal models of inflammatory pain and neuropathic pain as well as enhanced mechanical allodynia following inflammation [9, 10]. Interestingly, A 1 R-/- mice also show enhanced sensitization following inflammation and nerve injury . Thus, deficiencies in adenosine production or A1R signaling cause similar behavioral phenotypes.
In support of an A1R-dependent mechanism, we found that intrathecal (i.t.) injection of secretory PAP protein (from mouse or human) into wild-type mice had long lasting antinociceptive, antihyperalgesic and antiallodynic effects that were entirely dependent on A1R activation [10, 11]. These data suggested that spinal delivery of PAP protein could be used therapeutically to generate adenosine and activate A1R over an extended time period. Likewise, direct activation of A1R with adenosine or selective A1R agonists had antinociceptive effects in rodents and humans [13–31].
Considering that both PAP and NT5E generate adenosine, we hypothesized that NT5E protein might also have A1R-dependent antinociceptive effects. However, we were unable to test this hypothesis because mammalian NT5E protein was not available. As emphasized in a recent review by Colgan and colleagues, this lack of a reliable source of purified protein has hindered studies with NT5E . Others used 5'-nucleotidase protein purified from rattlesnake (Crotalus atrox) venom instead [4, 32, 33]. Crotalus 5'-nucleotidase had no deleterious effects when injected intraperitoneally and rescued phenotypes in Nt5e-/- mice; however, possible toxicity from venom contaminants remains a concern--especially if this venom-derived protein were to be used in the nervous system.
To overcome these toxicity concerns, we purified and characterized (in vitro and in vivo) a secretory version of recombinant mouse NT5E. Our present study builds upon work by Servos and colleagues who purified a recombinant but non-secretory version of rat NT5E using the baculovirus expression system .
Purification of soluble mouse NT5E using the baculovirus expression system
Two days after infecting Hi5 insect cells with recombinant baculovirus we detected GST-mNT5E protein in the tissue culture supernatant at approximately 10 mg/L. This observation suggested that exclusion of Ser523 was important for producing a soluble version of NT5E. Additionally, based on SDS-PAGE and western blotting, the GST-mNT5E found in the medium was largely intact whereas cell lysates contained truncated and intact versions of mNT5E-GST (data not shown). We next purified mNT5E from the culture supernatant in two steps (see Methods). We reasoned that GST, a protein that binds glutathione, might interfere with physiological or behavioral studies if administered in vivo. So as part of our purification procedure, the GST fusion was removed by thrombin cleavage. Protein purity was analyzed under denaturing conditions with GelCode Blue protein stain (Figure 1B) and western blotting with an anti-NT5E antibody (Figure 1C). We observed a single band at ~62 kDa, corresponding to the calculated molecular weight of unglycosylated mNT5E with a (His)6 tag (61.7 kDa). No additional bands were observed, indicating that mNT5E protein was intact.
mNT5E has long lasting antinociceptive effects that are A1R dependent
Adenosine and selective A1R agonists have well-studied antinociceptive effects in rodents and humans [26, 40, 41]. These agonists are often delivered intrathecally to avoid side effects associated with peripheral A1R activation . However, A1R agonists do have side effects when delivered intrathecally at high doses, including overt motor paralysis [10, 43]. These motor side effects are likely due to activation of A1R on motor neurons . Our present study indicates that NT5E, an ectonucleotidase that hydrolyzes AMP to adenosine, provides an alternative means of activating A1R for therapeutic purposes without causing overt motor paralysis. Although PAP also has A1R-dependent antinociceptive effects when injected intrathecally [10, 11], PAP shares no sequence similarity to NT5E. This lack of similarity made it impossible for us to determine a priori if recombinant mNT5E would be catalytically active, stable and effective when tested in live animals.
As previously discussed , ectonucleotidases are catalytically restricted in that they generate adenosine in proportion to substrate availability. Catalytic restriction limits the amount of adenosine produced and could explain why saturating doses of PAP or NT5E protein do not paralyze mice. Moreover, adenosine can be eliminated from the extracellular space by nucleoside transporters and metabolic enzymes, including adenosine deaminase and adenosine kinase [40, 44]. These competing processes of adenosine production and elimination place an upper limit on how much extracellular adenosine is available to activate A1R in animals. In support of this, adenosine deaminase inhibitors and adenosine kinase inhibitors prolong the extracellular bioavailability of adenosine and have antinociceptive effects in animals [17, 21, 45, 46].
Unexpectedly, our studies revealed that two molecularly distinct ectonucleotidases (PAP and NT5E) have pronounced antinociceptive effects that persist for an extended time period (2-3 days). This long duration of action in vivo could not have been predicted from the biochemical properties of these enzymes alone. More importantly, our findings suggest ectonucleotidases represent a new class of antinociceptive drugs with potential therapeutic advantages over adenosine, A1R agonists and inhibitors of adenosine metabolism. For example, the long duration of action of ectonucleotidases could be useful in situations where there is a need to provide a sustained level of A1R activation. Moreover, recombinant NT5E could be used to further study the role of NT5E in pain mechanisms and to study many other physiological processes that are regulated by NT5E [2, 9].
The GST-mNT5E baculovirus expression plasmid was generated by PCR amplification of mouse NT5E (nt 131-1696 from GenBank accession # NM_011851.3) using Phusion polymerase and a full-length expression construct of mNT5E as template. Primer sequences contained EcoRI sites (in bold italics) to facilitate cloning into pAcSecG2T (BD Biosciences). N-terminal primer: 5'-cgcgaattc attgggagctcacgatcctgcacaca. C-terminal (His)6 tag primer: 5'-gcggaattc ttaatgatgatgatgatgatggaacttgatccgcccttcaacg. These primers amplify a product that contains the catalytic domain of mNT5E fused to the (His)6 epitope tag but that lacks the signal peptide and GPI anchor sequence (located at Ser523). This mNT5E PCR product was subcloned in frame with an N-terminal GST fusion tag, with a single thrombin cleavage site between the GST tag and the coding sequence of mNT5E. The final plasmid was sequence verified.
mNT5E protein purification
The GST-mNT5E plasmid was used to generate recombinant mNT5E protein using the BD BaculoGold Expression System (BD Biosciences). Briefly, we infected Hi5 insect cells with high-titer recombinant baculovirus, incubated the cells for 48 hours at 27°C and then removed the cells from the supernatant by centrifugation. The supernatant containing secreted GST-mNT5E was filtered (0.45 μm pore size, Millipore) and concentrated in PBS (10 mM sodium phosphate, 140 mM NaCl, pH 7.4) using a Millipore cartridge with a 10 k retention cutoff. The concentrated supernatant was loaded onto a 5 mL GSTrap FF column (GE Healthcare) using a peristaltic pump at 4°C. Loading was performed overnight at a slow flow rate (0.4 mL/min. for 14-16 hours) to optimize binding of the GST-tagged protein. The column was then washed with 50 mL PBS. Purified thrombin (GE Healthcare, Cat. # 27-0846-01) was added to 2 mL of PBS (250 U thrombin/L of expression culture) and loaded onto the GSTrap column using a syringe. The on-column cleavage reaction proceeded for 16 hours at room temperature. The pre-loaded GSTrap column was then attached to an ÄKTA Explorer chromatography system with UV monitoring. Cleaved mNT5E and thrombin were eluted in PBS while the GST tag remained bound to the column. Fractions were monitored by SDS-PAGE to estimate purity, mNT5E concentration and cleavage efficiency (~80%). The cleaved mNT5E was separated from thrombin using a Superdex75 10/300 GL column attached to the ÄKTA Explorer system. Proteins were eluted in PBS at a flow rate of 0.5 mL/min. A maximum of 500 μL was injected per run. Fractions containing cleaved mNT5E were pooled, concentrated and then dialyzed against 0.9% saline. Protein purity was confirmed by SDS-PAGE, staining for total protein with GelCode Blue (Pierce/Thermo Scientific, Cat. # 24590) and western blotting with anti-NT5E antibody (R&D Systems, AF4488). Amersham full-range rainbow molecular weight markers (GE Healthcare) were used for SDS-PAGE and western blots. Recombinant mNT5E was kept at 4°C for short-term (1-2 months) use and at -80°C for long term storage.
Enzymatic reactions (50 μL final) were carried out with recombinant mNT5E at 37°C for 3 minutes in 100 mM HEPES, pH 7.0, 4 mM MgCl2 with adenosine 5'-monophosphate disodium salt (Fluka, 01930) as substrate. Reactions were terminated by adding 950 μL of the malachite green color reagent [0.03% (w/v) malachite green oxalate, 0.2% (w/v) sodium molybdate, 0.05% (v/v) Triton X-100, dissolved in 0.7 M HCl] followed by incubation at room temperature for 30 minutes. Inorganic phosphate was quantified by measuring OD650 and comparing to an inorganic phosphate (KH2PO4) standard curve . Unit (U) definition: 1 U hydrolyzes 1 nmol of AMP per minute at 37°C at pH 7.0. α,β-me-ADP was purchased from Sigma (M3763).
All behavioral experiments involving vertebrate animals were approved by the Institutional Animal Care and Use Committee at the University of North Carolina at Chapel Hill. C57BL/6 mice, 2-4 months old, were purchased from Jackson Laboratories. A 1 R-/- mice were backcrossed to C57BL/6J mice for 12 generations [48, 49]. Male mice were used for all behavioral studies and were acclimated to the testing room, equipment and experimenter for at least three days before testing. To further reduce variability in behavioral studies, mice were almost exclusively tested when in the resting or light sleep behavioral state . The experimenter was blind to genotype during behavioral testing.
Thermal sensitivity was measured by heating one hindpaw with a Plantar Test apparatus (IITC) following the Hargreaves method . The radiant heat source intensity was calibrated so that a paw withdrawal reflex was evoked in ~10 s., on average, in wild-type C57BL/6 mice. Cutoff time was 20 s. One measurement was taken from each paw per time point to determine paw withdrawal latency. Mechanical sensitivity was measured using a semi-flexible tip attached to an Electronic von Frey apparatus (IITC) as described elsewhere [52, 53]. The force values obtained with this apparatus are higher than the force values obtained using calibrated von Frey filaments . Three measurements were taken from each paw then averaged to determine paw withdrawal threshold in grams. To induce inflammatory pain, 20 μL complete Freund's adjuvant (MP Biomedicals) was injected into one hindpaw, centrally beneath glabrous skin, with a 30G needle. We performed spared nerve injury surgeries as described by Shields and colleagues . mNT5E protein was diluted in 0.9% saline for intrathecal injection (5 μL/mouse) using the direct lumbar puncture method . None of the mNT5E-injected mice displayed reduced mobility or paralysis following injection, as assessed by visually observing motor activity following injections.
We thank Yvette Chuang for excellent technical assistance, Jost Vielmetter, Inderjit Nangiana and Michael Anaya at the Caltech Protein Expression Center for purifying mNT5E protein. This work was supported by grants to MJZ from The Searle Scholars Program, The Klingenstein Foundation, The Whitehall Foundation, Rita Allen Foundation and NINDS (R01NS060725, R01NS067688). NAS was supported by NINDS (F30NS063507) and a MSTP grant (T32GM008719). MJZ is a Rita Allen Foundation Milton E. Cassel Scholar.
- Zimmermann H: 5'-Nucleotidase: molecular structure and functional aspects. Biochem J 1992,285(Pt 2):345–365.PubMed CentralPubMedGoogle Scholar
- Colgan SP, Eltzschig HK, Eckle T, Thompson LF: Physiological roles for ecto-5'-nucleotidase (CD73). Purinergic Signal 2006,2(2):351–360. 10.1007/s11302-005-5302-5PubMed CentralPubMedView ArticleGoogle Scholar
- Strohmeier GR, Lencer WI, Patapoff TW, Thompson LF, Carlson SL, Moe SJ, Carnes DK, Mrsny RJ, Madara JL: Surface expression, polarization, and functional significance of CD73 in human intestinal epithelia. J Clin Invest 1997,99(11):2588–2601. 10.1172/JCI119447PubMed CentralPubMedView ArticleGoogle Scholar
- Thompson LF, Eltzschig HK, Ibla JC, Wiele CJ, Resta R, Morote-Garcia JC, Colgan SP: Crucial role for ecto-5'-nucleotidase (CD73) in vascular leakage during hypoxia. J Exp Med 2004,200(11):1395–1405. 10.1084/jem.20040915PubMed CentralPubMedView ArticleGoogle Scholar
- Eltzschig HK, Ibla JC, Furuta GT, Leonard MO, Jacobson KA, Enjyoji K, Robson SC, Colgan SP: Coordinated adenine nucleotide phosphohydrolysis and nucleoside signaling in posthypoxic endothelium: role of ectonucleotidases and adenosine A2B receptors. J Exp Med 2003,198(5):783–796. 10.1084/jem.20030891PubMed CentralPubMedView ArticleGoogle Scholar
- Castrop H, Huang Y, Hashimoto S, Mizel D, Hansen P, Theilig F, Bachmann S, Deng C, Briggs J, Schnermann J: Impairment of tubuloglomerular feedback regulation of GFR in ecto-5'-nucleotidase/CD73-deficient mice. J Clin Invest 2004,114(5):634–642.PubMed CentralPubMedView ArticleGoogle Scholar
- Koszalka P, Ozuyaman B, Huo Y, Zernecke A, Flogel U, Braun N, Buchheiser A, Decking UK, Smith ML, Sevigny J, et al.: Targeted disruption of cd73/ecto-5'-nucleotidase alters thromboregulation and augments vascular inflammatory response. Circ Res 2004,95(8):814–821. 10.1161/01.RES.0000144796.82787.6fPubMedView ArticleGoogle Scholar
- Hunsucker SA, Mitchell BS, Spychala J: The 5'-nucleotidases as regulators of nucleotide and drug metabolism. Pharmacol Ther 2005,107(1):1–30. 10.1016/j.pharmthera.2005.01.003PubMedView ArticleGoogle Scholar
- Sowa NA, Taylor-Blake B, Zylka MJ: Ecto-5'-Nucleotidase (CD73) Inhibits Nociception by Hydrolyzing AMP to Adenosine in Nociceptive Circuits. J Neurosci 2010,30(6):2235–2244. 10.1523/JNEUROSCI.5324-09.2010PubMed CentralPubMedView ArticleGoogle Scholar
- Zylka MJ, Sowa NA, Taylor-Blake B, Twomey MA, Herrala A, Voikar V, Vihko P: Prostatic acid phosphatase is an ectonucleotidase and suppresses pain by generating adenosine. Neuron 2008,60(1):111–122. 10.1016/j.neuron.2008.08.024PubMed CentralPubMedView ArticleGoogle Scholar
- Sowa NA, Vadakkan KI, Zylka MJ: Recombinant mouse PAP Has pH-dependent ectonucleotidase activity and acts through A(1)-adenosine receptors to mediate antinociception. PLoS ONE 2009,4(1):e4248. 10.1371/journal.pone.0004248PubMed CentralPubMedView ArticleGoogle Scholar
- Wu WP, Hao JX, Halldner L, Lovdahl C, DeLander GE, Wiesenfeld-Hallin Z, Fredholm BB, Xu XJ: Increased nociceptive response in mice lacking the adenosine A1 receptor. Pain 2005,113(3):395–404. 10.1016/j.pain.2004.11.020PubMedView ArticleGoogle Scholar
- Gomes JA, Li X, Pan HL, Eisenach JC: Intrathecal adenosine interacts with a spinal noradrenergic system to produce antinociception in nerve-injured rats. Anesthesiology 1999,91(4):1072–1079. 10.1097/00000542-199910000-00028PubMedView ArticleGoogle Scholar
- Lavand'homme PM, Eisenach JC: Exogenous and endogenous adenosine enhance the spinal antiallodynic effects of morphine in a rat model of neuropathic pain. Pain 1999,80(1–2):31–36. 10.1016/S0304-3959(98)00193-6PubMedView ArticleGoogle Scholar
- Maione S, de Novellis V, Cappellacci L, Palazzo E, Vita D, Luongo L, Stella L, Franchetti P, Marabese I, Rossi F, et al.: The antinociceptive effect of 2-chloro-2'-C-methyl-N6-cyclopentyladenosine (2'-Me-CCPA), a highly selective adenosine A1 receptor agonist, in the rat. Pain 2007,131(3):281–292. 10.1016/j.pain.2007.01.013PubMedView ArticleGoogle Scholar
- Lee YW, Yaksh TL: Pharmacology of the spinal adenosine receptor which mediates the antiallodynic action of intrathecal adenosine agonists. J Pharmacol Exp Ther 1996,277(3):1642–1648.PubMedGoogle Scholar
- Poon A, Sawynok J: Antinociception by adenosine analogs and inhibitors of adenosine metabolism in an inflammatory thermal hyperalgesia model in the rat. Pain 1998,74(2–3):235–245. 10.1016/S0304-3959(97)00186-3PubMedView ArticleGoogle Scholar
- Cui JG, Sollevi A, Linderoth B, Meyerson BA: Adenosine receptor activation suppresses tactile hypersensitivity and potentiates spinal cord stimulation in mononeuropathic rats. Neurosci Lett 1997,223(3):173–176. 10.1016/S0304-3940(97)13435-8PubMedView ArticleGoogle Scholar
- Holmgren M, Hednar T, Nordberg G, Mellstrand T: Antinociceptive effects in the rat of an adenosine analogue, N6-phenylisopropyladenosine. J Pharm Pharmacol 1983,35(10):679–680.PubMedView ArticleGoogle Scholar
- Yoon MH, Bae HB, Choi JI: Antinociception of intrathecal adenosine receptor subtype agonists in rat formalin test. Anesth Analg 2005,101(5):1417–1421. 10.1213/01.ANE.0000180994.10087.6FPubMedView ArticleGoogle Scholar
- Jarvis MF, Mikusa J, Chu KL, Wismer CT, Honore P, Kowaluk EA, McGaraughty S: Comparison of the ability of adenosine kinase inhibitors and adenosine receptor agonists to attenuate thermal hyperalgesia and reduce motor performance in rats. Pharmacol Biochem Behav 2002,73(3):573–581. 10.1016/S0091-3057(02)00840-7PubMedView ArticleGoogle Scholar
- Aley KO, Levine JD: Multiple receptors involved in peripheral alpha 2, mu, and A1 antinociception, tolerance, and withdrawal. J Neurosci 1997,17(2):735–744.PubMedGoogle Scholar
- Zahn PK, Straub H, Wenk M, Pogatzki-Zahn EM: Adenosine A1 but not A2a receptor agonist reduces hyperalgesia caused by a surgical incision in rats: a pertussis toxin-sensitive G protein-dependent process. Anesthesiology 2007,107(5):797–806. 10.1097/01.anes.0000286982.36342.3fPubMedView ArticleGoogle Scholar
- Belfrage M, Segerdahl M, Arner S, Sollevi A: The safety and efficacy of intrathecal adenosine in patients with chronic neuropathic pain. Anesth Analg 1999,89(1):136–142. 10.1097/00000539-199907000-00023PubMedGoogle Scholar
- Eisenach JC, Hood DD, Curry R: Preliminary efficacy assessment of intrathecal injection of an American formulation of adenosine in humans. Anesthesiology 2002,96(1):29–34. 10.1097/00000542-200201000-00011PubMedView ArticleGoogle Scholar
- Eisenach JC, Rauck RL, Curry R: Intrathecal, but not intravenous adenosine reduces allodynia in patients with neuropathic pain. Pain 2003,105(1–2):65–70. 10.1016/S0304-3959(03)00158-1PubMedView ArticleGoogle Scholar
- Giffin NJ, Kowacs F, Libri V, Williams P, Goadsby PJ, Kaube H: Effect of the adenosine A1 receptor agonist GR79236 on trigeminal nociception with blink reflex recordings in healthy human subjects. Cephalalgia 2003,23(4):287–292. 10.1046/j.1468-2982.2003.00511.xPubMedView ArticleGoogle Scholar
- Fukunaga AF, Alexander GE, Stark CW: Characterization of the analgesic actions of adenosine: comparison of adenosine and remifentanil infusions in patients undergoing major surgical procedures. Pain 2003,101(1–2):129–138. 10.1016/S0304-3959(02)00321-4PubMedView ArticleGoogle Scholar
- Sollevi A, Belfrage M, Lundeberg T, Segerdahl M, Hansson P: Systemic adenosine infusion: a new treatment modality to alleviate neuropathic pain. Pain 1995,61(1):155–158. 10.1016/0304-3959(94)00187-JPubMedView ArticleGoogle Scholar
- Karlsten R, Gordh T Jr: An A1-selective adenosine agonist abolishes allodynia elicited by vibration and touch after intrathecal injection. Anesth Analg 1995,80(4):844–847. 10.1097/00000539-199504000-00037PubMedGoogle Scholar
- Lynch ME, Clark AJ, Sawynok J: Intravenous adenosine alleviates neuropathic pain: a double blind placebo controlled crossover trial using an enriched enrolment design. Pain 2003,103(1–2):111–117. 10.1016/S0304-3959(02)00419-0PubMedView ArticleGoogle Scholar
- Eckle T, Fullbier L, Wehrmann M, Khoury J, Mittelbronn M, Ibla J, Rosenberger P, Eltzschig HK: Identification of ectonucleotidases CD39 and CD73 in innate protection during acute lung injury. J Immunol 2007,178(12):8127–8137.PubMedView ArticleGoogle Scholar
- Hart ML, Much C, Gorzolla IC, Schittenhelm J, Kloor D, Stahl GL, Eltzschig HK: Extracellular adenosine production by ecto-5'-nucleotidase protects during murine hepatic ischemic preconditioning. Gastroenterology 2008,135(5):1739–1750. e1733 10.1053/j.gastro.2008.07.064PubMedView ArticleGoogle Scholar
- Servos J, Reilander H, Zimmermann H: Catalytically active soluble ecto-5'-nucleotidase purified after heterologous expression as a tool for drug screening. Drug Dev Res 1998, 45: 269–276. Publisher Full Text 10.1002/(SICI)1098-2299(199811/12)45:3/4<269::AID-DDR25>3.0.CO;2-BView ArticleGoogle Scholar
- Ogata S, Hayashi Y, Misumi Y, Ikehara Y: Membrane-anchoring domain of rat liver 5'-nucleotidase: identification of the COOH-terminal serine-523 covalently attached with a glycolipid. Biochemistry 1990,29(34):7923–7927. 10.1021/bi00486a021PubMedView ArticleGoogle Scholar
- Eisenhaber B, Bork P, Eisenhaber F: Prediction of potential GPI-modification sites in proprotein sequences. J Mol Biol 1999,292(3):741–758. 10.1006/jmbi.1999.3069PubMedView ArticleGoogle Scholar
- Crane JK, Shulgina I, Naeher TM: Ecto-5'-nucleotidase and intestinal ion secretion by enteropathogenic Escherichia coli. Purinergic Signal 2007,3(3):233–246. 10.1007/s11302-007-9056-0PubMed CentralPubMedView ArticleGoogle Scholar
- Schulte G, Robertson B, Fredholm BB, DeLander GE, Shortland P, Molander C: Distribution of antinociceptive adenosine A1 receptors in the spinal cord dorsal horn, and relationship to primary afferents and neuronal subpopulations. Neuroscience 2003,121(4):907–916. 10.1016/S0306-4522(03)00480-9PubMedView ArticleGoogle Scholar
- Reppert SM, Weaver DR, Stehle JH, Rivkees SA: Molecular cloning and characterization of a rat A1-adenosine receptor that is widely expressed in brain and spinal cord. Mol Endocrinol 1991,5(8):1037–1048. 10.1210/mend-5-8-1037PubMedView ArticleGoogle Scholar
- Sawynok J, Liu XJ: Adenosine in the spinal cord and periphery: release and regulation of pain. Prog Neurobiol 2003,69(5):313–340. 10.1016/S0301-0082(03)00050-9PubMedView ArticleGoogle Scholar
- Hayashida M, Fukuda K, Fukunaga A: Clinical application of adenosine and ATP for pain control. J Anesth 2005,19(3):225–235. 10.1007/s00540-005-0310-8PubMedView ArticleGoogle Scholar
- Jacobson KA, Gao ZG: Adenosine receptors as therapeutic targets. Nat Rev Drug Discov 2006,5(3):247–264. 10.1038/nrd1983PubMed CentralPubMedView ArticleGoogle Scholar
- Sawynok J: Adenosine and ATP receptors. Handb Exp Pharmacol 2007, 177: 309–328. full_textPubMedView ArticleGoogle Scholar
- Kowaluk EA, Jarvis MF: Therapeutic potential of adenosine kinase inhibitors. Expert Opin Investig Drugs 2000,9(3):551–564. 10.1517/135437188.8.131.521PubMedView ArticleGoogle Scholar
- Keil GJ, DeLander GE: Spinally-mediated antinociception is induced in mice by an adenosine kinase-, but not by an adenosine deaminase-, inhibitor. Life Sci 1992,51(19):PL171–176. 10.1016/0024-3205(92)90566-8PubMedView ArticleGoogle Scholar
- Poon A, Sawynok J: Antinociception by adenosine analogs and an adenosine kinase inhibitor: dependence on formalin concentration. Eur J Pharmacol 1995,286(2):177–184. 10.1016/0014-2999(95)00444-PPubMedView ArticleGoogle Scholar
- Lanzetta PA, Alvarez LJ, Reinach PS, Candia OA: An improved assay for nanomole amounts of inorganic phosphate. Anal Biochem 1979,100(1):95–97. 10.1016/0003-2697(79)90115-5PubMedView ArticleGoogle Scholar
- Hua X, Erikson CJ, Chason KD, Rosebrock CN, Deshpande DA, Penn RB, Tilley SL: Involvement of A1 adenosine receptors and neural pathways in adenosine-induced bronchoconstriction in mice. Am J Physiol Lung Cell Mol Physiol 2007,293(1):L25–32. 10.1152/ajplung.00058.2007PubMedView ArticleGoogle Scholar
- Johansson B, Halldner L, Dunwiddie TV, Masino SA, Poelchen W, Gimenez-Llort L, Escorihuela RM, Fernandez-Teruel A, Wiesenfeld-Hallin Z, Xu XJ, et al.: Hyperalgesia, anxiety, and decreased hypoxic neuroprotection in mice lacking the adenosine A1 receptor. Proc Natl Acad Sci USA 2001,98(16):9407–9412. 10.1073/pnas.161292398PubMed CentralPubMedView ArticleGoogle Scholar
- Callahan BL, Gil AS, Levesque A, Mogil JS: Modulation of mechanical and thermal nociceptive sensitivity in the laboratory mouse by behavioral state. J Pain 2008,9(2):174–184. 10.1016/j.jpain.2007.10.011PubMedView ArticleGoogle Scholar
- Hargreaves K, Dubner R, Brown F, Flores C, Joris J: A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 1988,32(1):77–88. 10.1016/0304-3959(88)90026-7PubMedView ArticleGoogle Scholar
- Cunha TM, Verri WA Jr, Vivancos GG, Moreira IF, Reis S, Parada CA, Cunha FQ, Ferreira SH: An electronic pressure-meter nociception paw test for mice. Braz J Med Biol Res 2004,37(3):401–407. 10.1590/S0100-879X2004000300018PubMedView ArticleGoogle Scholar
- Inoue M, Rashid MH, Fujita R, Contos JJ, Chun J, Ueda H: Initiation of neuropathic pain requires lysophosphatidic acid receptor signaling. Nat Med 2004,10(7):712–718. 10.1038/nm1060PubMedView ArticleGoogle Scholar
- Shields SD, Eckert WA, Basbaum AI: Spared nerve injury model of neuropathic pain in the mouse: a behavioral and anatomic analysis. J Pain 2003,4(8):465–470. 10.1067/S1526-5900(03)00781-8PubMedView ArticleGoogle Scholar
- Fairbanks CA: Spinal delivery of analgesics in experimental models of pain and analgesia. Adv Drug Deliv Rev 2003,55(8):1007–1041. 10.1016/S0169-409X(03)00101-7PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.